NCT03492528 Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"
| NCT ID | NCT03492528 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Condition | Cardiovascular Prognosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 530 participants |
| Start Date | 2019-07-05 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 530 participants in total. It began in 2019-07-05 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and oncologists who have developed a protocol for the monitoring and cardio-oncological management of patients treated for cancer. This unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined. Primary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology. Secondary objectives * To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data. * To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.
Eligibility Criteria
Inclusion Criteria: * All adults referred for specialist cardio-oncology consultations before the initiation of a cancer treatment according to pre-established indications will be eligible. Exclusion Criteria: * Failure to provide information that makes it impossible to complete a consultation form or refuse to sign the consent. * Minor or major patient under guardianship * Pregnant or breastfeeding woman
Contact & Investigator
jean-olivier ARNAUD
STUDY DIRECTOR
Assistance Publique-Hôpitaux de Marseille
Frequently Asked Questions
Who can join the NCT03492528 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Prognosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03492528 currently recruiting?
Yes, NCT03492528 is actively recruiting participants. Contact the research team at franck.thuny@ap-hm.fr for enrollment information.
Where is the NCT03492528 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT03492528 clinical trial?
NCT03492528 is sponsored by Assistance Publique Hopitaux De Marseille. The principal investigator is jean-olivier ARNAUD at Assistance Publique-Hôpitaux de Marseille. The trial plans to enroll 530 participants.